Breakthrough designation for 20-valent vac

December 13, 2018 0 By FM

Pfizer’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, received breakthrough therapy designation from the US FDA for the prevention of pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults.
The FDA decision is informed by the results of the 20vPnC Phase 2 randomized, double-blind trial to evaluate the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in adults 60 through 64 years of age.